FDA approves First RSV vaccine for adults under 60

Pfizer’s RSV vaccine cleared by FDA for use in some younger adults
Approval of Pfizer's Abrysvo in certain adults aged 18 to 59 years old will substantially expand the number of people eligible for vaccination with the shot.
The FDA has approved Pfizer’s RSV vaccine Abrysvo for adults aged 18 to 59
The US pharma giant Pfizer recently announced that its respiratory syncytial virus (RSV) vaccine Abrysvo has received FDA approval in adults aged 18 to 59 who are at an increased risk of developing lower respiratory tract disease caused by RSV (RSV-LRTD).
FDA expands Pfizer’s RSV vaccine label to include all high-risk adults
Abrysvo is now approved to prevent lower respiratory tract disease caused by RSV in high-risk adults aged over 18 years.
US FDA approves Pfizer's RSV vaccine for adults at increased risk of the disease
The U.S. Food and Drug Administration on Tuesday approved Pfizer's RSV vaccine for the prevention of lower respiratory tract disease caused by RSV in adults aged 18 to 59 at increased risk of the disease.
FDA OKs Pfizer’s RSV vaccine for some adults under 60
On Tuesday, the US Food and Drug Administration approved Pfizer’s respiratory syncytial virus (RSV) vaccine, Abrysvo, for people 18 to 59 who are more vulnerable to the virus.
Pfizer Receives FDA Approval for RSV Vaccine
Abrysvo can prevent lower respiratory tract disease caused by RSV for people between the ages of 18 and 59 who are at increased risk. It is the first RSV vaccine indicated for adults younger than 50,
Pfizer Wins FDA Approval of RSV Vaccine for Broader Adult Population
Pfizer’s Abrysvo is the first respiratory syncytial virus vaccine that can be used for adults less than 50 years of age. Tuesday’s label expansion covers younger adults who are deemed at higher risk of RSV-related lower respiratory tract disease.
Pfizer, Merck Pneumonia Shots Get Backing for Adults Over 50
A key panel of US health advisers voted in favor of lowering the age recommendation for vaccines made by Pfizer Inc. and ...
BioPharma Dive16h
Merck, Pfizer lifted as CDC backs broader use of pneumococcal vaccines
An agency panel recommended lowering the age for routine vaccination from 65 to 50, boosting the revenue outlook for multiple ...
devdiscourse2d
Pfizer Reaches 1 Billion Pneumococcal Vaccine Doses Supplied Through Gavi Partnership
In collaboration with Gavi, Pfizer has been instrumental in expanding access to lifesaving vaccines in low- and ...
USA Today1mon
What You Need to Know About Vaccines for Bacterial and Viral Diseases
which cause more than 160,000 deaths in children under age 5. Pfizer has extensive experience targeting pathogens to make effective vaccines that help prevent these illnesses. For example ...
The Washington Post10d
After Pfizer’s coronavirus vaccine success, CEO targeted for revenue slump
Barely three years ago, Pfizer was the toast of the pharmaceutical world and Bourla, who was elevated to the top job in 2019, wrote a book about the race to develop the coronavirus vaccine.
Q&A on the 2024-2025 COVID-19 Vaccines
Updated COVID-19 vaccines targeting JN.1-lineage omicron variants of the coronavirus are now available in the U.S. for the ...
Free children's flu vaccine clinics are today at sites in Green Bay and De Pere
GREEN BAY - You still have time to get your vaccines as the fall flu season and other respiratory illnesses start spreading.